Log in to search using one of your social media accounts:

 

FDA approves Gilead triple HIV drug, rival files lawsuit

(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Biktarvy, Gilead Sciences Inc's once-daily triple-combination tablet for treatment of HIV infection, paving the way for the biotech company to capture more of the multibillion-dollar HIV drug market.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Source: Current Problems in Cardiology - Category: Cardiology Source Type: research
Source: Current Problems in Cardiology - Category: Cardiology Source Type: research
Source: Current Problems in Cardiology - Category: Cardiology Source Type: research
Source: Current Problems in Cardiology - Category: Cardiology Source Type: research
Source: Current Problems in Cardiology - Category: Cardiology Source Type: research
Source: Current Problems in Cardiology - Category: Cardiology Source Type: research
Source: Cardiovascular and Haematological Disorders - Drug Targets - Category: Cardiology Authors: Tags: Articles Source Type: research
Source: Cardiovascular and Haematological Disorders - Drug Targets - Category: Cardiology Authors: Tags: Review article Source Type: research
Source: Cardiovascular and Haematological Disorders - Drug Targets - Category: Cardiology Authors: Tags: Review article Source Type: research
Source: Cardiovascular and Haematological Disorders - Drug Targets - Category: Cardiology Authors: Tags: Review article Source Type: research
More News: Biotechnology | Food and Drug Administration (FDA) | Health | Lawsuits | Legislation